Globus Medical (GMED) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St to open higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Globus Medical (GMED) PT Raised to $30 at BofA/Merrill Lynch Following Q4, Branch Deal
February 26, 2015 8:37 AM ESTBofA/Merrill Lynch analyst Bob Hopkins reiterated a Buy rating and boosted his price target on Globus Medical (NYSE: GMED) to $30.00 (from $26.00) following Q4 results and the acquisition of Branch.
Hopkins calls Branch a controversial but accretive deal. He also said guidance seems... More
